DDInter923 DDInter1956
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Cytarabine
Cytarabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Didanosine
Didanosine {u} (Compound) resembles {v} (Compound) Zalcitabine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Cytarabine
Cytarabine {u} (Compound) resembles {v} (Compound) Gemcitabine
Gemcitabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cytarabine
Cytarabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Didanosine
Didanosine {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Zalcitabine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Cytarabine
Cytarabine {u} (Compound) resembles {v} (Compound) Decitabine
Decitabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Poliovirus type 1 antigen (formaldehyde inactivated)
Poliovirus type 1 antigen (formaldehyde inactivated) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cytarabine
Cytarabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Etonogestrel {u} (Compound) causes {v} (Side Effect) Pollakiuria
Pollakiuria {u} (Side Effect) is caused by {v} (Compound) Zalcitabine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Cytarabine
Cytarabine {u} (Compound) binds {v} (Gene) DCK
DCK {u} (Gene) is bound by {v} (Compound) Zalcitabine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cytarabine
Cytarabine {u} (Compound) resembles {v} (Compound) Zalcitabine
Infliximab may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine (Compound) resembles Zalcitabine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine (Compound) resembles Zalcitabine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine (Compound) resembles Gemcitabine (Compound) and Gemcitabine (Compound) resembles Zalcitabine (Compound)
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine (Compound) resembles Zalcitabine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Zalcitabine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine (Compound) resembles Decitabine (Compound) and Decitabine (Compound) resembles Zalcitabine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine (Compound) resembles Zalcitabine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel (Compound) causes Pollakiuria (Side Effect) and Pollakiuria (Side Effect) is caused by Zalcitabine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine (Compound) binds DCK (Gene) and DCK (Gene) is bound by Zalcitabine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine (Compound) resembles Zalcitabine (Compound)